Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TLRY
TLRY logo

TLRY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.650
Open
5.630
VWAP
5.54
Vol
3.32M
Mkt Cap
659.02M
Low
5.475
Amount
18.41M
EV/EBITDA(TTM)
37.57
Total Shares
119.60M
EV
718.50M
EV/OCF(TTM)
--
P/S(TTM)
0.70
Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. Its adult-use portfolio offers a range of products, from flowers to beverages. Its beverage-alcohol portfolio includes a selection of craft beer, spirits, and beverages.
Show More

Events Timeline

(ET)
2026-04-23
13:10:00
Roth Capital: Cannabis Products Rescheduled to Schedule 3
select
2026-04-23
10:30:00
Trump Orders Medical Marijuana Products to Schedule III
select
2026-04-23
10:00:00
Trump Signs Order to Reschedule Medical Marijuana to Schedule III
select
link
2026-04-22 (ET)
2026-04-22
12:00:00
Trump Administration Expected to Reclassify Cannabis on Wednesday
select
link
2026-04-22
12:00:00
Tilray Trading Resumes
select
2026-04-22
11:50:00
Tilray Trading Halted Due to High Volatility
select

News

Fool
7.5
05-27Fool
Cannabis Industry Disappointment: Tilray's Uncertain Future
  • Industry Underperformance: Despite high hopes from Wall Street, Tilray Brands has seen its stock price decline over 90% in the past five years, reflecting the overall disappointing performance of the cannabis industry and diminishing investor confidence.
  • Policy Change Opportunity: The U.S. government's decision to move certain cannabis products from Schedule I to Schedule III may facilitate medical cannabis research; however, it does not legalize cannabis at the federal level, leaving significant legal barriers for transportation and operations.
  • Operational Efficiency Challenges: The illegality of interstate shipping forces Tilray and other cannabis companies to establish production facilities in each state, leading to significantly higher operating costs, which impacts profitability, even as policy changes may reduce some business expenses.
  • Increased Competitive Pressure: Although Tilray has diversified its offerings and is now the fourth-largest craft brewer in the U.S., it faces competition from larger corporations post-potential federal legalization, and the lack of a clear competitive advantage raises uncertainties about its future prospects.
NASDAQ.COM
7.0
05-27NASDAQ.COM
U.S. Cannabis Regulatory Landscape Improves
  • Industry Underperformance: Despite improvements in the U.S. cannabis regulatory environment, Tilray Brands has seen its stock price decline over 90% in the past five years, indicating a broader industry underperformance that undermines investor confidence in future growth.
  • Regulatory Changes Impact: The FDA's reclassification of certain cannabis products from Schedule I to Schedule III will facilitate medical cannabis research; however, it does not legalize cannabis federally, maintaining legal barriers for interstate shipping that lead to high operational costs for companies.
  • Increased Market Competition: Although Tilray offers a diverse range of CBD and cannabis products in the U.S. market, it may face intense competition from larger corporations with superior brand recognition and financial resources, potentially diminishing Tilray's market position.
  • Financial Concerns: Despite becoming the fourth-largest craft brewer in the U.S. through acquisitions, Tilray continues to struggle with inconsistent revenue growth and ongoing losses, leading analysts to generally view the company's long-term outlook as unattractive, advising investors to proceed with caution.
NASDAQ.COM
9.5
05-27NASDAQ.COM
Tilray's Fundamentals Improve, But Regulatory Changes Needed for Growth
  • International Business Surge: In its Q3 2026 report, Tilray's international cannabis segment achieved a remarkable 73% year-over-year sales growth, indicating strong performance in the European market, despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which may lay a foundation for future profitability.
  • Adjusted EBITDA Improvement: The company's adjusted EBITDA rose from $9 million to $10.7 million, reflecting a 19% year-over-year increase, showcasing progress in cost control and operational efficiency, which could bolster investor confidence moving forward.
  • Dependence on U.S. Regulation: Despite improvements in fundamentals, Tilray's stock price remains highly dependent on the progress of cannabis rescheduling in the U.S.; a successful transition to Schedule III could significantly enhance its market value, while failure to do so may exert downward pressure.
  • Caution for Investors: While Tilray garners attention in the market, analysts note that other cannabis stocks operating at the state level may present clearer catalysts and potentially higher returns, prompting investors to exercise caution when considering Tilray as an investment option.
Fool
9.5
05-27Fool
Tilray Brands Shows Improved Fundamentals but Needs U.S. Rescheduling to Accelerate Growth
  • Significant International Growth: In its Q3 2026 earnings report, Tilray's international cannabis business achieved a remarkable 73% year-over-year sales growth, indicating strong potential in global markets despite overall net revenue and gross profit growth being modest at 11% and 6%, respectively, which enhances its future profitability prospects.
  • Improved Adjusted EBITDA: The company reported a 19% year-over-year increase in adjusted EBITDA, rising from $9 million to $10.7 million, demonstrating positive progress in cost control and operational efficiency, although it still faced a net loss of $25.2 million.
  • Stable Financial Guidance: Tilray's management reiterated its financial guidance for the fiscal year ending June 30, forecasting adjusted EBITDA between $62 million and $72 million, reflecting confidence in future performance, even as the market continues to undervalue the company.
  • U.S. Market Potential Unlocked: Despite ongoing discussions about the reclassification of marijuana, Tilray needs full legalization in the U.S. to leverage its cultivation capacity and enter this lucrative market, with current market valuation around $630 million indicating investor caution regarding future growth.
Newsfilter
1.0
05-26Newsfilter
Tilray Medical Joins Cannabis Europa 2026 Forum
  • Industry Forum Participation: Tilray Medical's involvement in Cannabis Europa London 2026 brings together policymakers, healthcare professionals, and industry leaders to discuss the future of medical cannabis regulation and science, highlighting the company's significant role in the sector.
  • Expert Panel Discussion: José Tempero, Director of International Medical Affairs, will participate in a panel titled 'Evidence First: Designing Public Policy Through Data and Trials,' emphasizing the importance of clinical research and real-world evidence in shaping responsible cannabis policy frameworks.
  • Patient Support Platform: Tilray Medical co-hosts the official afterparty for Cannabis Europa London 2026 with Lyphe Clinic, which focuses on supporting patient consultations and access to medical cannabis treatments, further advancing the company's patient-centric approach in Europe.
  • Global Market Positioning: Operating in over 20 highly regulated international markets, Tilray Medical supports hundreds of thousands of patients with pharmaceutical-grade cultivation, manufacturing, and distribution capabilities, showcasing its leadership in the global medical cannabis industry.
Fool
8.5
05-25Fool
Cannabis Market Potential Soars, Investment Opportunities Emerge
  • Optimistic Market Outlook: According to estimates from Fortune Business Insights, the global cannabis market could exceed $1.4 trillion by 2034, up from $138 billion this year, reflecting a significant growth potential with a compound annual growth rate exceeding 34%.
  • Policy Changes Impact: The recent rescheduling of FDA-approved marijuana products from Schedule I to Schedule III in the U.S. marks a significant milestone that could pave the way for future legalization, although no clear timeline exists yet, the government's consideration of marijuana benefits is a positive sign.
  • Investment Risks and Opportunities: Investing in cannabis stocks like Tilray Brands carries risks due to its frequent losses and cash burn, but its stock often surges during discussions of legalization, attracting growth-oriented investors looking for significant gains.
  • Advantages of Multi-State Operators: In addition to Tilray, multi-state operators such as Curaleaf Holdings and Trulieve Cannabis may benefit more directly from the rescheduling of marijuana in the U.S., making their market positions and potential returns important considerations for investors.
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
Wall Street analysts forecast TLRY stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
8.50
Averages
9.57
High
10.00
Current: 0.000
sliders
Low
8.50
Averages
9.57
High
10.00
Canaccord
Hold
downgrade
$13
AI Analysis
2026-04-02
Reason
Canaccord
Price Target
$13
AI Analysis
2026-04-02
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Tilray to C$9.50 from C$13 and keeps a Hold rating on the shares.
Roth Capital
Bill Kirk
Neutral
to
Buy
upgrade
$10
2026-04-01
Reason
Roth Capital
Bill Kirk
Price Target
$10
2026-04-01
upgrade
Neutral
to
Buy
Reason
Roth Capital analyst Bill Kirk upgraded Tilray to Buy from Neutral with an unchanged $10 price target. The firm is citing the company's core Canadian business holding steady, inflection in Tilray's international operations and improving beverage category, the analyst tells investors in a research note. Tilray shares are back at July 2025 levels, but the fundamental outlook has improved and the potential for regulatory change is greater, the firm added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TLRY
Unlock Now

Valuation Metrics

The current forward P/E ratio for Tilray Brands Inc (TLRY.O) is 1000.00, compared to its 5-year average forward P/E of 73.60. For a more detailed relative valuation and DCF analysis to assess Tilray Brands Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
73.60
Current PE
1000.00
Overvalued PE
389.57
Undervalued PE
-242.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
35.32
Current EV/EBITDA
-1.67
Overvalued EV/EBITDA
73.80
Undervalued EV/EBITDA
-3.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.89
Current PS
0.61
Overvalued PS
5.67
Undervalued PS
0.11

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

how is cannibis securities doing today
Intellectia · 8 candidates
Market Cap: >= 100.00MPrice: >= $1.00Themes: The Cannabis IndustryMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
CGC logo
CGC
Canopy Growth Corp
511.04M
TLRY logo
TLRY
Tilray Brands Inc
803.02M
SNDL logo
SNDL
SNDL Inc
391.39M
VFF logo
VFF
Village Farms International Inc
328.97M
ACB logo
ACB
Aurora Cannabis Inc
201.89M
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.49B
best day trade stock
Intellectia · 9 candidates
Price: $5.00 - $100.00Volume: >= 3,000,000Price Change Pct: >= $3.00Relative Vol: >= 2Beta: HighRisk
Ticker
Name
Market Cap$
top bottom
KODK logo
KODK
Eastman Kodak Co
1.10B
ORIC logo
ORIC
Oric Pharmaceuticals Inc
995.75M
LUNR logo
LUNR
Intuitive Machines Inc
5.20B
RLAY logo
RLAY
Relay Therapeutics Inc
2.24B
GSAT logo
GSAT
Globalstar Inc
10.00B
AEHR logo
AEHR
Aehr Test Systems
1.36B
what penny stocks to buy pre market 4/1/26
Intellectia · 14 candidates
Market Cap: 100.00M - 2.00BRegion: USVolume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $20.00
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
753.80M
OMER logo
OMER
Omeros Corp
748.71M
VOR logo
VOR
Vor Biopharma Inc
871.44M
VALN logo
VALN
Valneva SE
542.98M
SLNO logo
SLNO
Soleno Therapeutics Inc
1.73B
SGMO logo
SGMO
Sangamo Therapeutics Inc
102.28M
Give me the top 5 cannabis companies
Intellectia · 4 candidates
Market Cap: >= 500.00MRevenue Ttm: >= 100.00MRegion: USThemes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.52B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.43B
CRON logo
CRON
Cronos Group Inc
947.63M
TLRY logo
TLRY
Tilray Brands Inc
736.32M
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
what cannabis stocks would you buy?
Intellectia · 4 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryQuarter Revenue Yoy Growth: >= 0.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
SNDL logo
SNDL
SNDL Inc
386.25M
ACB logo
ACB
Aurora Cannabis Inc
204.15M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
which. cannabisindustry should I invest in
Intellectia · 2 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
Cannibus stocks
Intellectia · 4 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryBeta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M

Whales Holding TLRY

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Tilray Brands Inc (TLRY) stock price today?

The current price of TLRY is 5.51 USD — it has decreased -2.48

What is Tilray Brands Inc (TLRY)'s business?

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. Its adult-use portfolio offers a range of products, from flowers to beverages. Its beverage-alcohol portfolio includes a selection of craft beer, spirits, and beverages.

What is the price predicton of TLRY Stock?

Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tilray Brands Inc (TLRY)'s revenue for the last quarter?

Tilray Brands Inc revenue for the last quarter amounts to 206.73M USD, increased 11.28

What is Tilray Brands Inc (TLRY)'s earnings per share (EPS) for the last quarter?

Tilray Brands Inc. EPS for the last quarter amounts to -0.24 USD, decreased -97.24

How many employees does Tilray Brands Inc (TLRY). have?

Tilray Brands Inc (TLRY) has 2842 emplpoyees as of May 30 2026.

What is Tilray Brands Inc (TLRY) market cap?

Today TLRY has the market capitalization of 659.02M USD.